Fuente: FierceBiotech After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with fleshing out Pfizer’s $43 billion Seagen acquisition into an antibody-drug conjugate empire while accelerating a PD-1xVEGF bispecific licensed from 3SBio toward 2028 readouts amid heated competition.